Becker's Healthcare August 5, 2025
CMS is proposing a five-year experiment that would allow state Medicaid programs and Medicare Part D plans to cover GLP-1s for weight management on a voluntary basis, according to an Aug. 1 report from The Washington Post.
Ozempic, Wegovy, Mounjaro and Zepbound would be included in the program, along with Eli Lilly’s oral GLP-1, Orforglipron, if it’s approved next year.
The program would begin in April 2026 for Medicaid and January 2027 for Part D plans and will be conducted by the Center for Medicare and Medicaid Innovation, according to the report. The proposal is not final and could still go through a public feedback process.
In April, CMS chose not to move forward with the Biden administration’s proposal to...
Today's Sponsors
Today's Sponsor